Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: Implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody

International Journal of Gynecological Cancer

Volumn 21, Issue 9, 2011, Pages 1613-1621

  Bignotti, Eliana ^a   Ravaggi, Antonella ^a   Romani, Chiara ^a   Falchetti, Marcella ^a   Lonardi, Silvia ^a   Facchetti, Fabio ^a   Pecorelli, Sergio ^a   Varughese, Joyce ^b   Cocco, Emiliano ^b   Bellone, Stefania ^b   Schwartz, Peter E ^b   Rutherford, Thomas J ^b   Santin, Alessandro D ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endometrial cancer; Endometrioid carcinoma; Immunotherapy; Natural killer cells; Trop 2 protein

Indexed keywords

CELL SURFACE MARKER; HUMAN IMMUNOGLOBULIN; HUMANIZED MONOCLONAL TROP 2 ANTIBODY; TROPHOBLAST CELL SURFACE MARKER 2; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; COMPLEMENT; IMMUNOGLOBULIN G; MESSENGER RNA; MONOCLONAL ANTIBODY; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; ENDOMETRIAL ENDOMETRIOID CARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOSYNTHESIS; CELL DIFFERENTIATION; ENDOMETRIUM TUMOR; GENETICS; IMMUNOLOGY; PASSIVE IMMUNIZATION; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CARCINOMA, ENDOMETRIOID; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; RNA, MESSENGER;

EID: 84857424342     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318228f6da     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17. (Pubitemid 13194678)
3. Deligdisch L, Cohen CJ. Histologic correlates and virulence implication of endometrial carcinoma associated with adenomatous hyperplasia. Cancer. 1985;56:1452-1455. (Pubitemid 15230596)
4. Bignotti E, Ravaggi A, Tassi RA, et al. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer. 2008;99:768-773.
5. Lipinski M, Parks DR, Rouse RV, et al. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci U S A. 1981;78:5147-5150. (Pubitemid 12229690)
6. Miotti S, Canevari S, Menard S, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer. 1987;39:297-303. (Pubitemid 17038183)
7. Alberti S, Miotti S, Stella M, et al. Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma. 1992;11:539-545.
8. Nakashima K, Shimada H, Ochiai T, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004;112:1029-1035. (Pubitemid 39507010)
9. Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science. 1997;276: 1268-1272. (Pubitemid 27227367)
10. Muhlmann G, Spizzo G, Gostner J, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 2009;62:152-158.
11. Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99:1290-1295.
12. Fong D, Spizzo G, Gostner JM, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 2008;21:186-191. (Pubitemid 351172170)
13. Fang YJ, Lu ZH, Wang GQ, et al. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 2009;24:875-884.
14. Bignotti E, Todeschini P, Calza S, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010;46:944-953.
15. Stein R, Basu A, Chen S, et al. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer. 1993;55:938-946. (Pubitemid 24005338)
16. Stein R, Govindan SV, Mattes MJ, et al. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides. Clin Cancer Res. 1999;5:3079s-3087s. (Pubitemid 29493899)
17. Govindan SV, Stein R, Qu Z, et al. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat. 2004;84:173-182. (Pubitemid 38393367)
18. Varughese J, Cocco E, Bellone S, et al. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer. 2011;117:3163-3172.
19. Cubas R, Li M, Chen C, et al. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009;1796:309-314.
20. Guerra E, Trerotola M, Dell' Arciprete R, et al. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res. 2008;68:8113-8121.
21. Wang J, Day R, Dong Y, et al. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther. 2008;7:280-285. (Pubitemid 351302522)